NPHP4 and acute lymphoblastic leukemia: The aberrant expression decreased along with the reduction of ALL blast cells, as assessed by flow cytometry after induction therapy (Fig. 2b), indicating that ACOT7–NPHP4 may serve as a molecular biomarker, and may have contributed to the failure to the induction therapy because of chemoresistance to doxorubicin.